Cardiology

"Risk estimators do not prescribe a drug," says Dr Lloyd-Jones. They are tools to help make the decision to prescribe the drug. He explains how to use them in primary care.

ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.

Research shows that increased risk of chronic disease and mortality begins below a BMI classified as obesity. The earlier we intervene with at-risk patients, the greater the chance for success.

Authors of a new study say their findings suggest bariatric surgery should be considered first-line treatment for the management of obesity in patients with type 2 diabetes.

Among more than 2 million Americans admitted to the hospital for cannabis use, those with a cardiac arrhythmia were more than 4 times more likely to die while hospitalized than those without.

Long time cardiometabolic investigator Harold Bays, MD, talks about obesity, new drugs to treat the disease, and how the words "be inefficient" could change thinking about treatment.

Sex disparities in cardiovascular care in the VA system included less therapy with antiplatelet agents and any intensity statin for women with premature ASCVD than men.

A new study found that mobile-based ECG screening for AF could improve health outcomes among American Indian adults who have historically endured greater health disparities.

Study authors warn that ASA added to a medication regimen may be unintentional and call on clinicians to assess patients on DOACs for concomitant ASA and deprescribe.

Results of a new study show that young adults who exercise up to 5 hours per week have a reduced risk of developing hypertension later in life.

Keith C Ferdinand, MD, discusses how deeply-rooted social determinants of health have led to the vastly disproportionate impact of COVID-19 on persons of color.

Measures of heart function and anatomy were used to assess the effects of red and processed meat on cardiovascular health; findings were reported at ESC Preventive Cardiology 2021.

The indicator of vascular protection against atherosclerotic progression was inversely associated with incident CV events, independent of traditional CVD biomarkers and improved Framingham Risk Score prediction.

Post-hoc analysis of the SPRINT trial found greater time spent with systolic blood pressure in target range was significantly associated with decreased risk of MACE.

Jackson Heart Study participants who maintained a healthy BP, BMI, and never smoked were at lower risk for incident CVD, suggesting targets for intervention in high-risk populations.

In individuals with chronic coronary disease, the presence of diabetes increased the rate of death by 38% during a 5-year follow-up period in analysis of a worldwide patient registry.

A recent meta-analysis suggests some sodium glucose cotransporter-2 inhibitor agents may protect against atrial and ventricular arrhythmias as well as sudden cardiac death in type 2 diabetes patients.

Healthcare providers are advised to weigh carefully the risks vs benefits of continuing lamotrigine therapy and not to substitute with another drug from the class.

In a subanalysis of the landmark DAPA-HF trial, dapagliflozin benefits were observed in both men and women, an important finding given variable response to cardiovascular drugs among women.

Influenza vaccination is associated with lower risk for all-cause and cardiovascular death in patients with CVD vs no vaccination, a new meta-analysis found.

The new consensus document is the first to offer personalized advice on the most effective exercises to lower blood pressure based on a patient's current blood pressure level.

ENDO 2021: A meta-analysis found increased cardiometabolic risk among Black women with PCOS vs White counterparts even though fasting glucose levels were comparable and triglyceride levels lower.

ENDO 2021: Obese individuals treated with semaglutide 2.4 mg vs placebo demonstrated improvements in body composition paralleling weight loss that may reduce risk for cardiometabolic disease.

Preliminary findings being presented at the International Stroke Conference 2021 show some of the same risk factors associated with stroke in older adults also cause stroke in younger adults.

International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.